Zobrazeno 1 - 9
of 9
pro vyhledávání: '"PB Senese"'
Publikováno v:
British Journal of Pharmacology. 165:2771-2786
BACKGROUND AND PURPOSE Drug candidates must be thoroughly investigated for their potential cardiac side effects. During the course of routine toxicological assessment, the compound RO5657, a CCR5 antagonist, was discovered to have the rare liability
Autor:
Dinah Misner, Kyle L. Kolaja, Sushmita Chanda, Justin Q. Ly, E. Meierhenry, D. Rotstein, M. Gralinski, Stefan Platz, Mark R. Fielden, Mudher Albassam, PB Senese, Liang Guo, Hirdesh Uppal, C. Frantz
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 60:235
Autor:
Rosas PC; Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago., Neves LAA; CorDynamics, Inc.; neves@cordynamics.com., Senese PB; CorDynamics, Inc., Gralinski MR; CorDynamics, Inc.
Publikováno v:
Journal of visualized experiments : JoVE [J Vis Exp] 2023 Jan 20 (191). Date of Electronic Publication: 2023 Jan 20.
Autor:
Rubio-Beltrán E; Division of Pharmacology, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands., Labastida-Ramírez A; Division of Pharmacology, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands., Haanes KA; Division of Pharmacology, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands., van den Bogaerdt A; Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands., Bogers AJJC; Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands., Zanelli E; Research and Development, Déclion Pharmaceuticals, Inc., Marblehead, Massachusetts., Meeus L; Euroscreen Fast Services Unit, Epics Therapeutics SA, Gosselies, Belgium., Danser AHJ; Division of Pharmacology, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands., Gralinski MR; CorDynamics, Inc., Chicago, Illinois., Senese PB; CorDynamics, Inc., Chicago, Illinois., Johnson KW; Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana., Kovalchin J; Research and Development, CoLucid Pharmaceuticals, Inc., Cambridge, Massachusetts., Villalón CM; Pharmacobiology, Cinvestav-Coapa, Mexico City, Mexico., MaassenVanDenBrink A; Division of Pharmacology, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Publikováno v:
British journal of pharmacology [Br J Pharmacol] 2019 Dec; Vol. 176 (24), pp. 4681-4695. Date of Electronic Publication: 2019 Nov 07.
Autor:
Misner DL; Celgene Corporation, San Diego, CA, USA., Frantz C, Guo L, Gralinski MR, Senese PB, Ly J, Albassam M, Kolaja KL
Publikováno v:
British journal of pharmacology [Br J Pharmacol] 2012 Apr; Vol. 165 (8), pp. 2771-86.
Autor:
Zopf DA; Corridor Pharmaceuticals, Inc., Towson, MD, USA., das Neves LA, Nikula KJ, Huang J, Senese PB, Gralinski MR
Publikováno v:
European journal of pharmacology [Eur J Pharmacol] 2011 Nov 16; Vol. 670 (1), pp. 195-203. Date of Electronic Publication: 2011 Sep 02.
Autor:
Sellers RS; Purdue Pharma, 444 Saw Mill River Road, Ardsley, NY 10502, USA. rani.sellers@pharma.com, Senese PB, Khan KN
Publikováno v:
Drug and chemical toxicology [Drug Chem Toxicol] 2004 May; Vol. 27 (2), pp. 111-22.
Autor:
Senese PB; Monsanto Safety Evaluation; Pharma Sector, Searle, Skokie IL 60077., Gralinski MR, Khan KN
Publikováno v:
Contemporary topics in laboratory animal science [Contemp Top Lab Anim Sci] 1999 Sep; Vol. 38 (5), pp. 42-43.
Autor:
Khan KN; G. D. Searle & Co, Skokie, IL 60077, USA., Komoscar WJ, Das I, Lazzaro NC, Senese PB, Hamilton P, Roth A, Smith PF
Publikováno v:
Contemporary topics in laboratory animal science [Contemp Top Lab Anim Sci] 1996 Sep; Vol. 35 (5), pp. 63-6.